论文部分内容阅读
目的:探讨结缔组织生长因子(CTGF)在肾间质纤维化中的表达情况及中药杜仲的干预作用。方法:采用单侧输尿管梗阻(UUO)肾间质纤维化模型。将32只大鼠随机分为4组,每组8只,即假手术组、模型组、厄贝沙坦组和杜仲组。厄贝沙坦组给予厄贝沙坦10mg.kg-1.d-1、杜仲组给予杜仲6g.kg-1.d-1治疗。术后2周处死大鼠,光镜下观察M asson及HE染色肾间质纤维化指数,观察肾组织病理改变,应用免疫组化方法检测肾组织CTGF的表达。结果:(1)UUO组与假手术组相比,BUN、Scr水平均显著增加,杜仲组较UUO组呈下降趋势。厄贝沙坦组作用效果与杜仲组相似,且两组间比较,无显著差异(P>0.05)。(2)与假手术组相比,肾组织行HE染色UUO组见广泛的肾小管上皮细胞空泡变性、扩张、部分萎缩,偶见坏死、肾间质增宽、大量的炎细胞浸润和间质纤维化,肾小球病理改变不明显,杜仲组上述改变均有所减轻,厄贝沙坦组病理改变与杜仲组相似,且两组间比较,无显著差异(P>0.05)。(3)与假手术组相比,M asson染色示UUO组可见大量胶原纤维增生,肾间质增宽,肾小球病变不明显,杜仲组上述改变均减轻,厄贝沙坦组病理改变与杜仲组相似,且两组间比较,无显著差异(P>0.05)。(4)假手术组大鼠肾间质有少量CTGF表达,染色为颗粒状,着色稀疏;UUO组CTGF表达明显增多,呈不均匀棕黄色颗粒状,肾小球表达不明显;杜仲组CTGF表达较UUO组明显降低,厄贝沙坦组CTGF表达与杜仲组相似,且两组间比较,无显著差异(P>0.05)。结论:杜仲可通过抑制CTGF的过度表达,进而减缓肾纤维化的病程进展。
Objective: To investigate the expression of connective tissue growth factor (CTGF) in renal interstitial fibrosis and the intervention of Chinese herbal medicine Duzhong. METHODS: Unilateral ureteral obstruction (UUO) renal interstitial fibrosis model was used. Thirty-two rats were randomly divided into 4 groups of 8 in each group, namely sham operation group, model group, irbesartan group and eucommia ulmoides group. Irbesartan group was given Irbesartan 10mg.kg-1.d-1, Eucommia group was given Eucommia 6g.kg-1.d-1 treatment. The rats were sacrificed 2 weeks after operation. The renal interstitial fibrosis index was stained by Mr Asson and HE under light microscope. The renal pathological changes were observed. The expression of CTGF was detected by immunohistochemistry. Results: (1) Compared with the sham-operated group, the UUO group had significantly increased BUN and Scr levels, and the Eucommia group showed a decreasing trend compared with the UUO group. The effect of irbesartan group was similar to that of the Eucommia group, and there was no significant difference between the two groups (P>0.05). (2)Compared with the sham-operated group, renal tubular HE staining of UUO group showed extensive degeneration of tubular epithelial cells, dilation, partial atrophy, occasional necrosis, widening of renal interstitial mass, massive inflammatory cell infiltration, and The fibrosis and pathological changes of the glomeruli were not obvious. The above changes in the Eucommia group were all alleviated. The pathological changes in the Irbesartan group were similar to those in the Eucommia group, and there was no significant difference between the two groups (P>0.05). (3) Compared with the sham operation group, M asson staining showed that a large number of collagen fibrosis, widened renal interstitial, and glomerular lesions were not evident in the UUO group. The above changes in the Duzhong group were all reduced, and the pathological changes in the irbesartan group were similar to those in the sham operation group. The Eucommia group was similar, and there was no significant difference between the two groups (P>0.05). (4) In the sham-operated group, a small amount of CTGF was expressed in the renal interstitium in the sham-operated group. The staining was granular and sparse in coloration. The expression of CTGF in the UUO group increased significantly, showing uneven brown-yellow granules with no obvious glomerular expression; CTGF expression in the Eucommia group Compared with UUO group, CTGF expression in irbesartan group was similar to that in Eucommia group, and there was no significant difference between the two groups (P>0.05). Conclusion: Eucommia can reduce the progression of renal fibrosis by inhibiting the overexpression of CTGF.